Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.

Start Date01 Nov 2026

Sponsor / Collaborator

Medical College of Wisconsin

NCT07796620

/ Not yet recruitingPhase 1/2IIT

Sirolimus+Ruxolitinib+Mycophenolate Mofetil Regimen for Prophylaxis of Acute Graft-versus-host Disease (aGvHD) in Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Who Are Intolerant to Calcineurin Inhibitor

Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled. At present, the standard prophylaxis for GVHD is cyclosporine combined with methotrexate. However, calcineurin inhibitors (CNI) can cause some vital side effects, which are not tolerated by some patients. Therefore, this study aims to explore the safety and efficacy of Sirolimus in combination with Ruxolitinib and Mycophenolate Mofetil for the prophylaxis of GVHD in patients with haplo-HSCT who are intolerant to calcineurin inhibitors.

Start Date01 Oct 2026

Sponsor / Collaborator

Peking University People's Hospital

NCT07524530

/ Not yet recruitingPhase 2IIT

Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies

Background:
Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with. Stem cell transplants are used to treat many diseases including blood cancers. Stem cell transplantation for patients with germline RUNX1 mutation driven blood cancers is standard of care and available in most major medical centers. The difference with this transplantation protocol is that it is prospective, only available to participants with germline RUNX1 variants and designed to determine the extent to which tailoring chemotherapy and supportive care medication doses for each individual patient may improve outcomes compared to data derived from retrospective transplantation protocols for patients with RUNX1 varinats which is less accurate.
Objective:
The primary objective of this protocol is to determine how tailored doses of chemotherapy and supportive care medications may improve disease free survival as compared to historical/expected disease free survival.
Eligibility:
People aged 4 to 70 years with blood cancer caused by a RUNX1 gene mutation. Other participants are also needed: (1) stem cell donors; (2) relatives who do not have a mutation in the RUNX1 gene; and (3) healthy volunteers.
Design:
Participants with blood cancer will be screened during approximately 1-3 months before transplatation. They will have blood tests and tests of their heart and lung function. A sample of bone marrow may be taken.
A flexible tube (central line) will be inserted into a vein in participants' chest or lower neck. This line will remain in place during the hospitalization and be used to draw blood and administer drugs. These lines are almost always transitioned to a peripherally inserted central catheter (PICC) line at the time of hospital discharge.
Participants will be inpatient for 4 to 5 weeks. They will receive drugs to prepare their body for the stem cell transplant. Some may also receive radiation treatment. Other tests will include imaging scans. The stem cell transplant will be given through the central line.
After discharge from the clinic, participants will have follow-up visits at least once per week for approximately 100 days. Then they will have follow-up clinic visits for 3 years.
Donors, relatives, and healthy volunteers may provide samples of blood, stool, and saliva. Adults may also opt to provide samples of skin and bone marrow.

Start Date21 Sep 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Mycophenolate Mofetil

100 Translational Medicine associated with Mycophenolate Mofetil

100 Patents (Medical) associated with Mycophenolate Mofetil

22,340

Literatures (Medical) associated with Mycophenolate Mofetil

31 Dec 2026·JOURNAL OF INVESTIGATIVE SURGERY

Laparoscopic Ultrasound-Guided Biopsy: A Safe and Effective Approach for Diagnosing Idiopathic Retroperitoneal Fibrosis

Article

Author: Li, Zhi-De ; Ma, Zhi-Gang ; Chen, Xiong ; Zhuo, Qian ; Li, Yu-Peng ; Meng, Yuan

BACKGROUND:

Idiopathic retroperitoneal fibrosis (IRPF) is a rare fibroinflammatory condition that is challenging to distinguish from retroperitoneal malignancies based solely on imaging. We evaluated laparoscopic ultrasound-guided biopsy for diagnosing IRPF.

METHODS:

We retrospectively analyzed 12 patients with suspected retroperitoneal fibrosis who underwent laparoscopic ultrasound-guided biopsy. The surgical technique involved systematic laparoscopic exploration, intraoperative ultrasound to delineate the mass and its relation to great vessels, and targeted biopsy.

RESULTS:

Preoperative imaging suggested retroperitoneal masses in all 12 patients but failed to provide a definitive diagnosis in any case. Laparoscopic biopsy was successfully performed in all patients without conversion to laparotomy. Pathological examination confirmed IRPF in 11 patients and retroperitoneal adenocarcinoma in one. The procedure was safe, with minimal blood loss (20.4 ± 14.8 mL) and a short operative time (68.3 ± 19.0 min). All IRPF patients were treated with a combination of prednisone, tamoxifen, and mycophenolate mofetil, leading to significant lesion regression on follow-up imaging (median 37.9 months).

CONCLUSIONS:

Laparoscopic ultrasound-guided biopsy is a safe and highly effective diagnostic procedure for IRPF. It provides definitive pathological diagnosis to guide appropriate therapy and should be considered when percutaneous biopsy is not feasible.

31 Dec 2026·Emerging Microbes & Infections

FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis

Article

Author: Xiao, Gengfu ; Wang, Lei ; Qi, Nan ; Ma, Kaixiong ; Zhou, Peiwen ; Hu, Huina ; Wang, Shaobo ; Ai, Qiangyun ; Ye, Zuodong ; Huang, Shanzhi ; He, Yang ; Zhou, Minmin ; Wang, Qingxing

ABSTRACTRespiratory syncytial virus (RSV), a leading cause of severe lower respiratory tract infections in pediatric and elderly populations, presents an urgent need for improved therapeutic interventions. Although ribavirin (RBV) is an FDA-approved antiviral for treating RSV, its clinical application is constrained by dose-dependent toxicity and limited therapeutic efficacy. Here, we developed a high-throughput system to screen FDA-approved drugs that enhance RBV's antiviral efficacy. Unlike conventional combination therapies, this approach does not require both components to demonstrate direct antiviral activity; rather, it enhances antiviral efficacy by targeting cellular pathways, even when the synergistic agents exhibit minimal antiviral effects as monotherapies. We identified mycophenolate mofetil (MMF) and its active metabolite, mycophenolic acid (MPA), clinically approved inhibitors of inosine monophosphate dehydrogenase (IMPDH), which significantly enhance the antiviral efficacy of RBV against RSV. Mechanistically, through IMPDH knockdown and exogenous GTP supplementation, we propose that MMF and MPA reduce intracellular GTP levels by inhibiting IMPDH activity, thereby enhancing RBV incorporation and improving its antiviral efficacy. Our studies show that IMPDH inhibitors and RBV work synergistically to combat both RSV A/B genotypes and human metapneumovirus (hMPV) in vitro. Importantly, we further validated the therapeutic potential of this combination in a mouse model, showing enhanced viral clearance and reduced pathogenesis. These findings suggest that the combination of IMPDH inhibitors with RBV represents a promising therapeutic strategy for RSV and hMPV infection in clinical settings.

31 Dec 2026·RENAL FAILURE

Kidney transplantation in sub-Sahara African countries: challenges and lessons from the experience of Cameroon: a preliminary report of the first 17 pioneer cases

Article

Author: Fokou, Marcus ; Tiam, Magne ; Essissima, Foe ; Ngongang, Marie Paule ; Aghogue, Tekounegning ; Ashuntantang, Gloria ; Tebere, Hawa ; Nono, Aristide ; Djientcheu, Vincent de Paul ; Kamga, Justin ; Ngoundjou, Amada ; Mba, Sebastien

This report presents the outcomes, challenges, and lessons learned from the first 17 cases of kidney transplantation (KT) performed in Cameroon and the Central Africa sub-region. All patients who underwent kidney transplantation at the Yaoundé General Hospital (YGH) are included in this study. Seventeen kidney transplants were performed, nine females and eight males. All donors were family members. The underlying nephropathies were chronic glomerulonephritis (9 cases), hypertensive nephropathy (6 cases), and Unknown origin (4 cases). Immunological compatibility was categorized as follows: HLA-identical (7 pairs), HLA-different (3 pairs), haploidentical (6 pairs), homozygous twin sisters (1 pair) and HLA semi-identical (1 pair). After transplantation, two recipients experienced complications due to an incorrect ureteral implantation into the peritoneum (1 case), and an anastomotic leak (hematoma), another case. All our patients are currently alive, with good quality of life and stable renal function. The treatment protocol was by induction therapy; basiliximab (20 mg on days 0 and 4) or Thymoglobulin, combined with methylprednisolone while maintenance therapy included mycophenolic acid, cyclosporine or tacrolimus, and prednisone. The total cost of patient management, including immune compatibility testing for the first patients, was covered by YGH and its partners. In conclusion, kidney transplantation is a safe and effective treatment in Cameroon. The team at YGH, along with international collaborators, have successfully acquired the necessary technology, and expertise, to perform kidney transplantation, making it a viable option for patients.

178

News (Medical) associated with Mycophenolate Mofetil

31 Aug 2026

·www.prnewswire.com

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients

First participant dosed in Phase 2 RENGEVITY-201 study evaluating pegrizeprument (VEL-101) in kidney transplant recipients Pegrizeprument is being developed as a novel maintenance immunosuppressive therapy for the prevention of organ rejection in transplant recipients This clinical milestone reinforces Veloxis' leadership and long-standing commitment to innovation in transplantation CARY, N.C., Aug. 31, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase 2 clinical trial [NCT07290777] of pegrizeprument, a novel investigational maintenance immunosuppressive agent being studied for prevention of organ rejection in kidney transplant recipients. "Advancing pegrizeprument into a Phase 2 study is an important clinical milestone for Veloxis and brings us one step closer to offering a potential new innovative therapy in a field where opportunities for meaningful innovation remain significant. We're grateful to the participants, investigators, and study teams making this trial possible," said Carl Kraus, MD, Chief Medical Officer of Veloxis. The Phase 2 study, RENGEVITY-201, is a randomized, multicenter, partially blinded, active control trial evaluating the safety and efficacy of pegrizeprument compared with tacrolimus in the prevention of organ rejection in patients undergoing kidney transplantation. Up to 120 de novo kidney transplant recipients will receive rATG with corticosteroids and mycophenolate as maintenance therapy and will be randomized 1:1:1 to receive either pegrizeprument (one of two doses) or tacrolimus. The primary objectives of the study will evaluate the safety, pharmacokinetics, and pharmacodynamics of pegrizeprument. "Our transplant franchise is built on a commitment to advancing care for transplant recipients through both established and investigational therapies," said Stacy Wheeler, Chief Executive Officer of Veloxis. "The continued development of pegrizeprument, together with ongoing investments in transplant-focused innovation, reflects our dedication to addressing important unmet needs and expanding future therapeutic possibilities for the transplant community." Kidney transplant recipients require life-long immunosuppression, often associated with complex dosing regimens and comorbid toxicities. Despite advancements in post-transplant clinical care, complications of immunosuppression and allograft rejection may negatively impact graft and patient survival. With an estimated 270,000 people living with a functioning kidney transplant in the United States, there remains a significant unmet need for new therapies that address these complications while maintaining adequate immunosuppression. About pegrizeprument Pegrizeprument is a pegylated monoclonal antibody fragment that binds to and blocks CD28‑mediated effector-T cell costimulation, without blocking CTLA-4, an important protein found on T cells that naturally helps keep the body's immune responses in check. Pegrizeprument is, therefore, expected to have a dual mechanism of action where in a direct manner, it blocks CD28‑mediated T cell activation, and indirectly, it allows for CTLA-4 mediated immunosuppressive functions. Pegrizeprument is currently being developed for the prevention of acute rejection in solid organ transplant recipients. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to pegrizeprument for the prevention of organ rejection in patients receiving a liver transplant in December 2025 and for the prophylaxis of heart allograft rejection in patients receiving a heart transplant in March 2026. Pegrizeprument, also known as VEL-101 and FR104, was licensed by Veloxis Pharmaceuticals, Inc. from OSE Immunotherapeutics in April 2021. As part of the license agreement, Veloxis Pharmaceuticals, Inc. obtained worldwide rights to develop, manufacture, and commercialize pegrizeprument for all transplant indications. About Veloxis Pharmaceuticals Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a global specialty pharmaceutical company committed to improving the lives of transplant and other immunocompromised patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of treatments that address areas of unmet needs in transplant medicine and serious infectious diseases. For further information, please visit Veloxis.com. About Asahi Kasei Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world's challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit . Contact: Veloxis Pharmaceuticals Anna Michaels Director, Corporate Communications [email protected] Media David Rosen Argot Partners [email protected] 646-461-6387 SOURCE Veloxis Pharmaceuticals 21% more press release views with Request a Demo

License out/inPhase 2Orphan DrugImmunotherapy

01 Jul 2026

·www.pharmaceutical-technology.com

Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

The New England Journal of Medicine has retracted Tavneos’ pivotal study paper upon request of two academic authors associated with it. Credit: Grand Warszawski / Shutterstock.com. In another blow to the future market prospects of Amgen’s rare disease therapy, Tavneos (avacopan), the New England Journal of Medicine (NEJM) has retracted the drug’s pivotal study paper. This comes after two academic authors associated with the paper requested its removal after an ongoing post-publication investigation by the US Food and Drug Administration (FDA) revealed that primary endpoint assessments in nine patients enrolled onto the trial were “readjudicated after database lock and trial unblinding”. This factor, the editors say, was “not disclosed in the article and is inconsistent with proper research conduct”, in a retraction notice from the NEJM . The 2021 paper’s removal from the NEJM database comes amid mounting scrutiny on the therapy’s risk-benefit profile from the FDA, as the agency’s drug review division proposed to withdraw Tavneos’ approval after uncovering “reasonable evidence of a causal association” between 76 cases of drug-induced liver injury – including eight deaths and seven cases of rare liver condition, vanishing bile duct syndrome (VBDS) – and the medicine’s use. The regulator also called the drug’s proven efficacy into question. The European Medicines Agency (EMA) recently took a similar stance to the FDA by calling for Tavneos’ market rollback at the end of June, after its own review of the Phase III Advocate study, which formed the foundations of Tavneos’ initial approval, was in breach of good clinical practice (GCP) guidelines. Amgen originally absorbed the US rights to Tavneos, a therapy for two rare inflammatory blood vessel conditions called microscopic polyangiitis (MPA) and severe, active granulomatosis with polyangiitis (GPA), through its $3.7bn 2022 takeover of the drug’s original developer, ChemoCentryx. Before the Committee for Medicinal Products for Human Use (CHMP) recommended revoking Tavneos’ approval, CSL Vifor commercialised the drug in Europe. Filling the European Tavneos gap As Amgen grapples with heightening regulatory hurdles linked to Tavenos’ place on the market, some new players are looking to fill the potential void left by the drug. This includes German biopharma company InflaRx, which is planning to engage with the EMA about the potential path to approval for two of its clinical-stage therapies, vilobelimab and izicopan, in ANCA-associated vasculitis – the umbrella term for the group of autoimmune diseases under which MPA and GPA sit. Currently, InflaRx is preparing izicopan for Phase II, while it considers vilobelimab to be “a Phase III-ready asset”. According to the company, these drugs provide a complementary biologic and oral pipeline “well positioned” to address the unmet needs of patients with AAV. According to GlobalData’s Pharmaceutical Intelligence Center, there are more than 30 ongoing clinical trials in Phase I-III for MPA and GPA, with a quarter of these being late-stage studies. GlobalData is the parent company of Pharmaceutical Technology .

Phase 2Phase 3Drug ApprovalAcquisitionAccelerated Approval

25 Jun 2026

·www.rochecanada.com

Gazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritis

The INESSS recommendation is the latest step towards public access to Gazyva (obinutuzumab) for persons with active lupus nephritis who are receiving standard therapy [1] Provincial jurisdictions will make the final decision on public reimbursement The INESSS recommendation is the latest step towards public access to Gazyva (obinutuzumab) for persons with active lupus nephritis who are receiving standard therapy [1] Provincial jurisdictions will make the final decision on public reimbursement MISSISSAUGA, ON, June 25, 2026 - Hoffmann-La Roche Limited (Roche Canada) is pleased to share that on June 3, 2026, the Institut national d’excellence en santé et en services sociaux (INESSS) recommended Gazyva (obinutuzumab) for public reimbursement in Quebec. This recommendation is for the treatment of persons with active lupus nephritis who are receiving standard therapy.[1] This positive recommendation expands the pathway to patient access, following Canada’s Drug Agency’s positive recommendation on May 6, 2026 and Health Canada's authorization in January 2026.[2,3] In Canada, lupus affects approximately 1 in 1,000 people.[4] Among those with lupus, nearly 40% develop lupus nephritis, a kidney-specific form of systemic lupus erythematosus (SLE).[5] SLE is a broader autoimmune disease that can affect various organs, such as the skin, joints, and blood system. Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, potentially leading to impaired kidney function or even kidney failure. “This positive recommendation from INESSS is an important milestone towards equitable access for patients with active lupus nephritis in Quebec,” said Simon Yunger, Vice-President, Value, Pricing and Reimbursement at Roche Canada. “This decision underscores the clear therapeutic value Gazyva delivers. Roche Canada remains fully committed to working with Quebec and all provincial and territorial jurisdictions to ensure Gazyva is made available swiftly through public drug plans.” The INESSS decision was supported by evidence from the phase III REGENCY study that showed nearly half of the participants (46.4%) on Gazyva in combination with standard therapy achieved a complete renal response compared to 33.1% on standard therapy alone.[6] Data showed a statistically significant reduction of corticosteroid use and an improvement in proteinuric response.[6] Roche Canada is delighted INESSS has recognized the clinical evidence and benefit shown by Gazyva for people in Quebec living with lupus nephritis. As the file proceeds to the pan-Canadian Pharmaceutical Alliance (pCPA) for pricing negotiations, we remain focused on securing broad public and private drug plan coverage across all provinces and territories. About Lupus Nephritis Lupus nephritis is a potentially life-threatening manifestation of systemic lupus erythematosus, an autoimmune disease that commonly affects the kidneys.[8] Lupus nephritis is characterised by an irreversible loss of nephrons, the filtering structures of the kidneys. Periods of intense disease activity, known as flares, can speed up the loss of nephrons and, if left unchecked, may lead to a progressive loss of kidney function. Even with the latest treatments, up to a third of people will progress to end-stage kidney disease, where dialysis or transplant are the only options and life expectancy and quality of life are substantially reduced.[9] About Gazyva Gazyva (obinutuzumab) is a Type II engineered humanized monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells.[11] In lupus nephritis, disease-causing B cells drive persistent inflammation that damages the kidneys and reduces their ability to function properly.[12] Data suggests that Gazyva depletes disease-causing B cells, helping to limit further damage to the kidneys and potentially preventing or delaying progression to end-stage kidney disease.[7] Gazyva is approved for adults with lupus nephritis in Canada, the United States and European Union and in over 100 countries for various types of haematological cancers. About the REGENCY Study REGENCY [NCT04221477] is a phase III, randomised, double-blind, placebo-controlled, multicentre study investigating the efficacy and safety of Gazyva (obinutuzumab) plus standard therapy (mycophenolate mofetil and glucocorticoids) in people with active/chronic International Society of Nephrology/Renal Pathology Society 2003 proliferative Class III or IV lupus nephritis, with or without Class V. The study enrolled 271 people, who were randomised 1:1 to receive either Gazyva plus standard therapy or placebo plus standard therapy. The study population was representative of the real-world population of people with lupus nephritis. About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and a sustainable healthcare system. Because we're committed to making quality healthcare accessible to everyone. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and the healthcare system expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs almost 2,000 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics division in Laval, Québec. For more information, please visit www.RocheCanada.com or follow Roche Canada on LinkedIn. Media Contact Jolinne Kearns Communications Manager Roche Canada 416-726-7699 mississauga.rochecanada@roche.com All trademarks used or mentioned are the property of its respective owners. References L’Institut national d’excellence en santé et en services sociaux: https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/gazyva-nephrite-lupique-active-7725.html Canada's Drug Agency - L'Agence des medicaments du Canada: https://www.cda-amc.ca/obinutuzumab Roche Canada, Health Canada authorizes Gazyva® (obinutuzumab) for adults with active lupus nephritis, January 2026. Available from: https://www.rochecanada.com/media/health-canada-authorizes-gazyva-obinutuzumab-for-adults-with-active-lupus-nephritis Lupus Canada; [cited 2026 January 7]. Available from: https://www.lupuscanada.org/what-is-lupus/ Hanly JG,et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb;55(2):252-62. Gazyva Product Monograph, January 22, 2026 Furie RA, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025 Feb;392:1471-83. Hocaoglu M et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network. Arthritis & Rheumatol 2023 Apr;75(4):567-573. Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Nat Rev Rheumatol. 2023 Apr;19(4):227-38. Anders HJ et al. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. Atisha-Fregoso Y, et al. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Investig. 2021 Jun 15;131(12):e149095. You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Mycophenolate Mofetil

External Link

KEGG	Wiki	ATC	Drug Bank
D00752	Mycophenolate Mofetil	L04AA06	DB00688

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nephrotic Syndrome	Japan	Chugai Pharmaceutical Co., Ltd.	19 Sep 2025
Interstitial lung disease due to systemic disease	Japan	Chugai Pharmaceutical Co., Ltd.	24 Jun 2024
Hematopoietic stem cell transplantation	Japan	Chugai Pharmaceutical Co., Ltd.	25 Jun 2021
Lupus Nephritis	Japan	Chugai Pharmaceutical Co., Ltd.	13 May 2016
Rejection of pancreas transplant	Japan	Chugai Pharmaceutical Co., Ltd.	09 Feb 2005
Cardiac transplant rejection	Japan	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Liver transplant rejection	Japan	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Lung transplant rejection	Japan	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Renal transplant rejection	Japan	Chugai Pharmaceutical Co., Ltd.	22 Dec 2000
Graft Rejection	United States	Roche Palo Alto LLC	03 May 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
acute leukemia	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Anaplastic Large-Cell Lymphoma	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Chronic Myelogenous Leukemia	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Diffuse Large B-Cell Lymphoma	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Follicular Lymphoma	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Immunoblastic Lymphadenopathy	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Lymphoma	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Myelodysplastic Syndromes	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Peripheral T-Cell Lymphoma	Phase 3	United States	Medical College of Wisconsin	25 Jun 2019
Uveitis	Phase 3	United States	The University of California, San Francisco	01 Aug 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03712878 (CTgov)	Phase 2	Hematologic Neoplasms	10	Allogeneic Hematopoietic Stem Cell Transplantation+Cyclophosphamide+Tacrolimus+mycophenolate mofetil	wqalslyszz = ddtofiqxps kkpxjzavtc (votqlqrjje, fmwvwqdyvg - jjfjcuxjdw) View more	-	23 Jul 2026
EULAR2026	Not Applicable	Vasculitis, Central Nervous System	216	Prednisone (PDN) monotherapy	hlbtpiymig(pksszgbmpx) = Aspirin use was associated with higher rates of therapy discontinuation (p = 0.044) and long-term remission (p = 0.009), but not reduced relapse frequency. tbfnryyheu (zoezzgasox ) View more	Positive	11 Jun 2026
				Prednisone (PDN) + Cyclophosphamide (CYC)
EULAR2026	Not Applicable	Scleroderma, Systemic	127	Mycophenolate mofetil (MMF) + Rituximab (RTX)	mcignttbbo(vbfrbwvtbf) = cuinqpigee frjtqwsvhe (qjovglfxlp )	Positive	11 Jun 2026
				Rituximab (RTX)	ddofslbaxa(esqhehicss) = wxdaegeuxj boifizoysl (zotytfzdyp )
EULAR2026	Not Applicable	Lupus Nephritis	66	Combination immunosuppressive therapy	qkrtrcvkft(yrajnoyzwx) = ugcwhpzggo ntvgdmswlt (lyohtsqkal ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Giant Cell Arteritis	47	Secukinumab	kshricmqdd(tudxluefux) = rdewuzugyn xfytnbvgan (oarftybybc ) View more	Positive	11 Jun 2026
				Jak inhibitors	vmcjyohcyp(gbzltydnvt) = tpzdxakxxc vprsjmotxp (oitblfuxvf ) View more
EULAR2026	Not Applicable	Interstitial lung disease due to systemic disease	191	immunosuppressive therapy	insqvcfdbu(rdmgiubxmz) = dqijxbcvzx zgxflhqggb (qdehzyliuu ) View more	Positive	11 Jun 2026
NCT02220985 (CTgov)	Phase 2	Recurrent Acute Leukemia \| Hematopoietic stem cell transplantation \| Acute Biphenotypic Leukemia ... View more	84	fludarabine phosphate+GCSF+tacrolimus+methotrexate+thiotepa (Arm A (MRD / High Intensity Conditioning))	gwjqsceydn = jgwovnytyx tfzianrscg (xeliitcwrl, hbkfqgwvad - fufoxryubi) View more	-	01 Jun 2026
				fludarabine phosphate+cyclophosphamide+GCSF+tacrolimus+Mycophenolate mofetil+thiotepa (Arm B (MRD / Low Intensity Conditioning))	gwjqsceydn = uccconnccg tfzianrscg (xeliitcwrl, rikssyolyu - ytdfgvemnk) View more
NCT05907746 (CTgov)	Phase 2	GATA2 Deficiency \| Immunologic Deficiency Syndromes	13	Total Body Irradiation+Fludarabine+Post-Transplant Cyclophosphamide+Tacrolimus+mycophenolate mofetil+Briquilimab (Arm A -Briquilimab, Fludarabine, 200 Centigray (cGy) Total Body Irradiation)	uzhykylchm = laoogsbawe gvjpvnkqwz (xgvxgfyjpc, gglbjtlwjh - cwuvooopmk) View more	-	29 May 2026
				Total Body Irradiation+Fludarabine+Post-Transplant Cyclophosphamide+Tacrolimus+mycophenolate mofetil+Briquilimab (Arm B - Briquilimab, Fludarabine, Cyclophosphamide, 200 Centigray (cGy) Total Body Irradiation)	uzhykylchm = ujvrdfmiul gvjpvnkqwz (xgvxgfyjpc, ibhxhynymu - dvuyzoklqe) View more
CAMARO (EASL2026)	Not Applicable	Hepatitis, Autoimmune First line \| Maintenance	65	Azathioprine (AZA) plus prednisolone	tjlmcavefe(vxmdrqiuzy) = jnwljpisjh twkmypekcw (btkaxvtdxv ) View more	Positive	27 May 2026
				Mycophenolate mofetil (MMF) plus prednisolone	tjlmcavefe(vxmdrqiuzy) = skkhqrwlul twkmypekcw (btkaxvtdxv ) View more
EASL2026	Not Applicable	Hepatitis, Autoimmune Second line	142	Mycophenolate mofetil	tlrpidgamq(jolfpgchsv) = osmugcncdt uomnstkaqt (fusgrnxwyd ) View more	Positive	27 May 2026
				Tacrolimus	tlrpidgamq(jolfpgchsv) = pixjkuhlnz uomnstkaqt (fusgrnxwyd )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis